摘要

利福平或多药耐药结核（TB）菌株（定义为至少联合利福平和异烟肼耐药） - MDR / RR-TB - 需要比药物易感TB更复杂，更昂贵的管理。 对耐多药/耐多药结核病的全球响应将决定是否实现了世界卫生组织（WHO）新的结核病战略中制定的目标。 2015年，世卫组织估计全球发生580,000例MDR / RR-TB事件和250,000例MDR / RR-TB死亡事件。 然而，向世卫组织提交的国家报告显示，全世界只有30％的结核病患者接受了MDR / RR-TB检测，其中22％符合条件的耐多药结核病治疗开始，并且其中一半以上成功完成了治疗。 迫切需要强有力的政治承诺和更多资金用于MDR / RR-TB的研究，普遍诊断和有效治疗。

Tuberculosis (TB) strains with rifampicin or multidrug resistance (defined as, at least, combined rifampicin and isoniazid resistance) – MDR/RR-TB – require more complex, costly management than drug-susceptible TB. The global response to MDR/RR-TB will determine if the targets set in the context of the new End TB Strategy of the World Health Organization (WHO) are achieved. In 2015, WHO estimated that 580,000 incident MDR/RR-TB cases and 250,000 MDR/RR-TB deaths occurred globally. However, country reports to WHO show that only 30% of TB patients notified worldwide are tested for MDR/RR-TB, 22% of those eligible start MDR-TB treatment and just over one half of them complete treatment successfully. Strong political commitment and increased funding for research and universal diagnosis and effective treatment for MDR/RR-TB are direly needed.

http://resistancecontrol.info/2017/drug-resistant-tuberculosis-what-is-the-situation-what-are-the-needs-to-roll-it-back-2/